Nestlé agreed on 1 September to sell seven of its supplement brands, including Nature's Bounty, Nuun and Osteo Bi-Flex, to the private equity firm Yellow Wood Partners for $1 billion. Those brands generated a total of $1.2 billion in sales last year alone, making the deal value them at under one times revenue. Nestlé bought these brands alongside a couple of others, as part of a $5.75 billion acquisition in 2021, making the sale a fraction of what was paid for them originally.
"Nature's Bounty isn't being bought as a science story, it's being bought as shelf presence."Michael Bush, GrowthWays Partners
That's because shelf presence, not research, is what these brands were built on. Nature's Bounty's growth has come from household name recognition, retail distribution and line extensions into whatever format is trending, gummies, drinks, on-the-go formats, rather than from a reputation for evidence. Nature's Bounty doesn't ignore research entirely, it runs its own innovation function and formulates with ingredients that have clinical backing, funded and run by other companies. It values the science; it just hasn't invested in generating its own.
Vitabiotics is the comparison. Bain Capital agreed to buy it in July, in a deal reported by The Times at around £900 million. The UK's largest vitamin company was founded nearly fifty years ago by Professor Kartar Lalvani, a scientist with a doctorate in medicinal chemistry, and still runs original clinical trials with universities and medical centres today.
Our read
The gap between these two deals isn't research spend, it's whether the research was ever run on the actual product being sold, rather than borrowed from someone else's study of an ingredient. Nature's Bounty's ingredients carry trials someone else designed and ran. Vitabiotics has run its own since 1971, when a scientist with a doctorate in medicinal chemistry founded the company on that principle, and continues to run trials on its own formulations today, making research and evidence the forefront of its brand identity.
A brand can put "science-backed" on a label. It cannot fake having run a trial on its own product and had a hospital put its name next to the result, decades running. That gap is real marketing power a label claim can't create, and it's most of the difference between a company bought for three times revenue and one bought for less than one. It's exactly the shift we're seeing in the brands we work with, they don't want to lean on category evidence, they want a body of product-specific evidence that becomes what the brand is actually known for.
Sources: PR Newswire, NutraIngredients, Bain Capital, The Times

